Brown Adipose Tissue as a Mechanistic Determinant of Semaglutide Treatment Response in Obesity (B… (NCT07621640) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Brown Adipose Tissue as a Mechanistic Determinant of Semaglutide Treatment Response in Obesity (BAT-Sema Study)
South Korea80 participantsStarted 2026-06
Plain-language summary
This study investigates whether the activity of brown adipose tissue (BAT) - a special type of fat that burns energy as heat - can predict how well individuals with obesity respond to semaglutide (Wegovy), a once-weekly injectable weight loss medication. Participants who are starting semaglutide treatment will undergo ¹⁸FDG-PET/CT imaging before and after 24 weeks of treatment. Prior to each PET/CT scan, participants will wear a water-circulating cooling vest to activate BAT. By measuring BAT activity at baseline and comparing it with the degree of weight loss and metabolic improvement at 24 weeks, the investigators aim to identify BAT as a predictive biomarker for personalized obesity treatment.
Who can participate
Age range
20 Years – 70 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Age 20-70 years at the time of enrollment
. Initiating semaglutide (Wegovy) treatment for obesity (newly starting treatment)
. BMI ≥ 27 kg/m² with at least one weight-related comorbidity:
. Ability and willingness to provide written informed consent
Exclusion criteria
. Diagnosis of type 1 or type 2 diabetes mellitus
. History of neck surgery or radiation therapy to the neck
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This study involves an ¹⁸FDG-PET/CT scan to measure brown fat activity before starting semaglutide — how much radiation exposure does that involve, and is that something I should be concerned about given my overall health situation?
2The trial isn't recruiting yet, so realistically how long might it be before I could even enroll, and is waiting that long a good idea compared to starting semaglutide treatment now on my own?
3This study seems focused on understanding why semaglutide works differently in different people rather than testing whether it works at all — does that mean I'd be taking semaglutide either way, and what are the implications if I have low brown fat activity going in?
4Since this is listed as Phase NA, which I understand often means it's more of an observational or mechanistic study than a treatment trial, does that change how confident you are about what I'd personally get out of participating versus just starting standard obesity treatment?
5Given that the study is measuring brown adipose tissue as a possible factor in how well semaglutide works, is there any way to know ahead of time whether my brown fat levels might make me a better or worse responder, and would that information actually change your treatment recommendations for me?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Correlation between baseline BAT metabolic activity (SUVmean and BAT volume on ¹⁸FDG-PET/CT) and percentage body weight loss at 24 weeks of semaglutide treatment
Timeframe: Baseline to 24 weeks
Trial details
NCT IDNCT07621640
SponsorHallym University
Sponsor typeOTHER
Study typeINTERVENTIONAL
Primary completion2028-02
Contact for this trial
Hun Jee Choe Hallym University Dongtan Sacred Heart Hospital, MD, PhD